Shanghai ZhenGe Biotechnology Co.,Ltd. announced that it has received $100,000,000 in its series C round of funding co-led by new investors Goldman Sachs Asset Management, L.P., Sofina Société Anonyme and Novo Holdings A/S on January 11, 2022. The transaction included participation from returning investors Shenzhen Co-win Venture Capital Investments Limited, IDG Capital Partners Co., Ltd., Lyfe Capital, Qiming Weichuang Venture Capital Management (Shanghai) Company Limited, and Junxin (Shanghai) Equity Investment Fund Management Co., Ltd. As a part of the transaction, Kevin Xu, Managing Director at Goldman Sachs Asset Management, L.P., has joined the company's board of directors. The company has raised $225,000,000 in funding till date.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
219.4 EUR | +1.95% | +3.59% | -2.66% |
04-24 | Tikehau Capital: 13% increase in assets under management in Q1 | CF |
03-28 | MORNING BID EUROPE-Yen traders on tenterhooks | RE |
1st Jan change | Capi. | |
---|---|---|
-2.66% | 7.78B | |
+16.54% | 75.59B | |
+53.03% | 16.95B | |
+3.20% | 15.78B | |
-0.77% | 12.3B | |
+9.67% | 12.04B | |
+6.24% | 10.88B | |
+34.86% | 10.17B | |
-1.71% | 9.7B | |
+53.23% | 7.88B |
- Stock Market
- Equities
- SOF Stock
- News Sofina SA
- Shanghai ZhenGe Biotechnology Co.,Ltd. announced that it has received $100 million in funding from a group of investors